<ol class="cite-this-references"><li id="reference-A178126">Takamura N, Maruyama T, Ahmed S, Suenaga A, Otagiri M: Interactions of aldosterone antagonist diuretics with human serum proteins. Pharm Res. 1997 Apr;14(4):522-6. [<a href="/articles/A178126" target="_blank">Article</a>] </li><li id="reference-A178069">LaCagnin LB, Lutsie P, Colby HD: Conversion of spironolactone to 7 alpha-thiomethylspironolactone by hepatic and renal microsomes. Biochem Pharmacol. 1987 Oct 15;36(20):3439-44. [<a href="/articles/A178069" target="_blank">Article</a>] </li><li id="reference-A178072">Los LE, Pitzenberger SM, Ramjit HG, Coddington AB, Colby HD: Hepatic metabolism of spironolactone. Production of 3-hydroxy-thiomethyl metabolites. Drug Metab Dispos. 1994 Nov-Dec;22(6):903-8. [<a href="/articles/A178072" target="_blank">Article</a>] </li><li id="reference-A178135">Kim GK, Del Rosso JQ: Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris: Practical Considerations for the Clinician Based on Current Data and Clinical Experience. J Clin Aesthet Dermatol. 2012 Mar;5(3):37-50. [<a href="/articles/A178135" target="_blank">Article</a>] </li><li id="reference-A178138">Millington K, Liu E, Chan YM: The Utility of Potassium Monitoring in Gender-Diverse Adolescents Taking Spironolactone. J Endocr Soc. 2019 Apr 4;3(5):1031-1038. doi: 10.1210/js.2019-00030. eCollection 2019 May 1. [<a href="/articles/A178138" target="_blank">Article</a>] </li><li id="reference-A178165">Karim A: Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability. Drug Metab Rev. 1978;8(1):151-88. doi: 10.3109/03602537808993782. [<a href="/articles/A178165" target="_blank">Article</a>] </li><li id="reference-A178192">Carone L, Oxberry SG, Twycross R, Charlesworth S, Mihalyo M, Wilcock A: Spironolactone. J Pain Symptom Manage. 2017 Feb;53(2):288-292. doi: 10.1016/j.jpainsymman.2016.12.320. Epub 2016 Dec 23. [<a href="/articles/A178192" target="_blank">Article</a>] </li><li id="reference-A11837">Sica DA: Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev. 2005 Jan;10(1):23-9. doi: 10.1007/s10741-005-2345-1. [<a href="/articles/A11837" target="_blank">Article</a>] </li><li id="reference-A178207">Gardiner P, Schrode K, Quinlan D, Martin BK, Boreham DR, Rogers MS, Stubbs K, Smith M, Karim A: Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol. 1989 Apr;29(4):342-7. [<a href="/articles/A178207" target="_blank">Article</a>] </li><li id="reference-A178243">Menard J: The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):45-52. doi: 10.1016/j.mce.2003.10.008. [<a href="/articles/A178243" target="_blank">Article</a>] </li><li id="reference-A178246">BOLTE E, VERDY M, MARC-AURELE J, BROUILLET J, BEAUREGARD P, GENEST J: Studies on new diuretic compounds: spirolactone and chlorothiazide. Can Med Assoc J. 1958 Dec 1;79(11):881-8. [<a href="/articles/A178246" target="_blank">Article</a>] </li><li id="reference-L6187">FDA Approved Drug Products: Spironolactone [<a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=012151" target="_blank">Link</a>] </li><li id="reference-L4449">FDA Approved Drug Products: Aldactone (spironolactone) tablets [<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/012151s062lbl.pdf" target="_blank">Link</a>] </li></ol>